View in browser Exciting scientific updates at WC12 and Eurotox 2023 We were delighted to participate in WC12 in Niagara Falls and Eurotox in Ljubljana during the past summer, where our team and partners delivered several posters and presentations.  Complex Samples, Mixtures, Quantitative Potency, Medical Devices, E&L Assessment and more This year's scientific theme brought attention to the non-animal GARD® sensitization assay and explored various aspects, including Difficult-to-Test, Quantitative Potency and Medical Devices.  Furthermore, our Group company ToxHub provided an in-depth exploration of E&L Assessment in their poster on mitigating risks in pharmaceutical applications. Recap Webinar on October 18 If you couldn't catch our poster and oral presentations at WC12 and Eurotox this year, we are hosting a free Recap Webinar on October 18. Register to engage in these new findings and our collaborative projects with industry partners!  Learn more about the key insights that will be shared during the webinar. 🎧 GARD® WEBINAR – LEARN MORE AND REGISTER! A major step towards the establishment of a fragrance industry tool for predicting NESIL values in QRA evaluations In a recent quantitative risk assessment project by IFF and RIFM, GARD®skin Dose-Response was considered to provide useful information for continuous predictions of skin sensitizing potency. The results demonstrate that the LLNA EC3 values and the human NESIL values predicted from the GARD®skin Dose-Response assay are reproducible between experiments and show good concordance with the published NESIL and EC3 values. Together with the reported performance data, this represents a major step towards the establishment of the assay as a relevant source of information to derive NESIL values for conducting QRA evaluations for fragrance materials to ensure product safety while avoiding the generation of new animal data. For more details, request a copy of the poster. New insights on Protein Allergens and Respiratory Sensitization A joint effort with Merck examined whether protein allergens share toxicity pathways with small molecules. The study highlights the successful use of GARD®air in predicting respiratory sensitization for the model allergen Subtilisin. Feel free to contact us to learn more about this new finding.  🗓️ BOOK A MEETING TO DISCUSS YOUR TOXICOLOGY ASSESSMENT NEEDS! Upcoming events 🎧 Webinar: Latest GARD® innovation & research in in vitro skin sensitization | Oct 18 🌎 Conference: ACT | Orlando, Florida | Nov 12-15 🌎 Conference: Annual Medical Device Biocompatibility Conference | Berlin | Nov 17 🌎 Conference: CFIC | Lyon, France | Nov 21-22 Copyright © SenzaGen 2023 All rights reserved. SenzaGen AB | Medicon Village | 223 81 Lund, Sweden You are receiving this email because you expressed interest in SenzaGen's technology in the past. Unsubscribe here if you do not wish to receive technology updates and news from us.